Medigen Vaccine Biologics
Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for th… Read more
Medigen Vaccine Biologics - Asset Resilience Ratio
Medigen Vaccine Biologics (6547) has an Asset Resilience Ratio of 36.49% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Medigen Vaccine Biologics's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Medigen Vaccine Biologics's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$1.48 Billion | 36.49% |
| Total Liquid Assets | NT$1.48 Billion | 36.49% |
Asset Resilience Insights
- Very High Liquidity: Medigen Vaccine Biologics maintains exceptional liquid asset reserves at 36.49% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Medigen Vaccine Biologics Industry Peers by Asset Resilience Ratio
Compare Medigen Vaccine Biologics's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Medigen Vaccine Biologics (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Medigen Vaccine Biologics.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 27.50% | NT$1.20 Billion | NT$4.36 Billion | -11.96pp |
| 2023-12-31 | 39.46% | NT$2.40 Billion | NT$6.09 Billion | -1.81pp |
| 2022-12-31 | 41.28% | NT$3.03 Billion | NT$7.35 Billion | +25.18pp |
| 2021-12-31 | 16.10% | NT$853.10 Million | NT$5.30 Billion | +14.58pp |
| 2020-12-31 | 1.52% | NT$53.17 Million | NT$3.49 Billion | -0.81pp |
| 2019-12-31 | 2.34% | NT$53.23 Million | NT$2.28 Billion | -20.68pp |
| 2018-12-31 | 23.02% | NT$502.52 Million | NT$2.18 Billion | +22.88pp |
| 2017-12-31 | 0.14% | NT$2.97 Million | NT$2.14 Billion | -1.15pp |
| 2016-12-31 | 1.29% | NT$23.46 Million | NT$1.82 Billion | +0.06pp |
| 2015-12-31 | 1.23% | NT$20.32 Million | NT$1.65 Billion | -32.62pp |
| 2014-12-31 | 33.85% | NT$411.20 Million | NT$1.21 Billion | -- |